Publicado

2019-01-01

Estudio proteómico 2DE-DIGE en plasma sanguíneo de pacientes en etapa infantil con leucemia linfoblástica aguda

2DE-DIGE proteomic study in blood plasma of patients in childhood stage with acute lymphoblastic leukemia

Estudo proteômico 2DE-DIGE no plasma sanguíneo de pacientes em estágio infantil com leucemia linfoblástica aguda

DOI:

https://doi.org/10.15446/rev.colomb.quim.v48n1.75170

Palabras clave:

Leucemia linfoblástica aguda, electroforesis bidimensional, proteómica comparativa, LC-MS/MS, proteínas de fase aguda, biomarcadores (es)
Acute lymphoblastic leukemia, two-dimensional electrophoresis, comparative proteomics, LC-MS/MS, acute phase proteins, biomarkers (en)
Leucemia linfoblastica aguda, eletroforese bidimensional, proteômica comparativa, LC-MS/MS, proteínas de fase aguda, biomarcadores (pt)

Descargas

Autores/as

En Colombia, durante la última década, la leucemia linfoblástica aguda (LLA) ha causado más del 40% de las muertes por cáncer en menores de edad. Entre los factores que influyen en estas cifras, el diagnóstico tardío es uno de los factores que más afecta el éxito del tratamiento. Por lo anterior, esta investigación se centró en el estudio del proteoma plasmático de niños colombianos diagnosticados con LLA tipo B, en comparación con controles en la búsqueda de proteínas que podrían ser clasificadas como biomarcadores de diagnóstico. En vista de los avances en las herramientas proteómicas y de espectrometría de masas y teniendo en cuenta que son una alternativa para abordar la complejidad molecular de enfermedades como el cáncer, se utilizó una aproximación proteómica basada en una separación por electroforesis bidimensional diferencial (2DE-DIGE) con posterior separación por cromatografía líquida acoplada a espectrometría de masas (LC-MS) en tándem. Se encontraron ocho proteínas con expresión diferencial en plasma de pacientes con LLA-B, entre las cuales resaltan la Serotransferrina, la Alfa-1-antitripsina, la Haptoglobina, la Alpha-2-glicoproteína de zinc y el Complemento C3.
In Colombia, during the last decade, acute lymphoblastic leukemia (ALL) has caused more than 40% of cancer deaths in children. Among the factors that influence these figures, late diagnosis is one of the factors that affects the treatment success. Therefore, this research focused on the plasma proteome study of Colombian children diagnosed with B-cell ALL, as compared with healthy controls in the search of proteins that could be classified as diagnostic biomarkers. Now, in view of the advances in the proteomics and mass spectrometry tools and taking into account that they are an alternative to address the molecular complexity of diseases such as cancer, a proteomic approach, based on bidimensional difference gel electrophoretic separation (2DE-DIGE) coupled to LC-MS/ MS, was used. We found eight differentially expressed proteins in plasma from B-cell ALL patients as follows: Serotransferrin, Alpha1-antitrypsin, Haptoglobin, Zinc-alpha-2- glycoprotein, and Complement C3.
Na Colômbia, durante a última década, a leucemia linfoblastica aguda (LLA) tem sido o câncer com maior incidência, com mais de 40% das mortes por câncer em menores atribuídas a essa doença. Entre os fatores que influenciam esses números, o diagnóstico tardio talvez seja o fator mais sensível que afeta negativamente o sucesso do tratamento. Esta pesquisa enfocou o estudo do proteoma plasmático de crianças colombianas diagnosticadas com LLA tipo B, dada a sua alta incidência, em comparação com controles na busca por proteínas que poderiam ter potencialidade para serem classificadas como biomarcadores diagnósticos. Agora, em vista dos avanços nas ferramentas de proteômica e espectrometria de massa e sabendo que eles são uma alternativa para abordar a complexidade molecular de doenças como o câncer, usamos uma abordagem proteômica baseada em uma separação por eletroforese bidimensional diferencial (2DE-DIGE) com subsequente separação por cromatografia líquida acoplada a espectrometria de massa em tandem. Encontramos 8 proteínas com expressão diferencial no plasma de pacientes com LBA, dentre os quais a Serotransferrina, a Alfa-1- antitripsina, a Haptoglobina, a Glicoproteína alfa-2-zinco e o Complemento C3.

Referencias

D. Bhojwani and J. J. Yang, “Biology of Childhood Acute Lymphoblastic Leukemia,” Pediatr Clin N Am, vol. 62, pp. 47–60, 2015.

W. L. Carroll, M. Loh, A. Biondi, and C. Willman, The Biology of Acute Lymphoblastic Leukemia. 2012.

A. V. Moorman, “New and emerging prognostic and predictive genetic biomarkers in B-cell precursor acute lymphoblastic leukemia,” Haematologica, vol. 101, no. 4, pp. 407–416, 2016.

M. P. Curado, T. Pontes, M. E. Guerra-Yi, and M. D. C. Cancela, “Leukemia mortality trends among children, adolescents, and young adults in Latin America.,” Rev. Panam. Salud Publica, vol. 29, no. 2, pp. 96–102, 2011.

A Suarez, M. Pina, D. X. Nichols-Vinueza, and J. Lopera, “A Strategy to Improve Treatment-Related Mortality and Abandonment of Therapy for Childhood ALL in a Developing Country Reveals the Impact of Treatment Delays,” Pediatr Blood Cancer, vol. 62, pp. 1395–1402, 2015.

C. Rodriguez-Galindo, P. Friedrich, P. Alcasabas, F. Antillon, S. Banavali, L. Castillo, T. Israels, S. Jeha, M. Harif, M. J. Sullivan, T. C. Quah, C. Patte, C. H. Pui, R. Barr, and T. Gross, “Toward the cure of all children with cancer through collaborative efforts: Pediatric oncology as a global challenge,” Journal of Clinical Oncology, vol. 33, no. 27. pp. 3065–3073, 2015.

G. Arentz, F. Weiland, M. K. Oehler, and P. Hoffmann, “State of the art of 2D DIGE,” Proteomics - Clin. Appl., vol. 9, pp. 277–288, 2015.

S. Viswanathan, M. Ünlü, and J. S. Minden, “Two-dimensional difference gel electrophoresis,” Nat. Protoc., vol. 1, no. 3, pp. 1351–1358, 2006.

A. Shevchenko, M. Wilm, O. Vorm, and M. Mann, “Mass Spectrometric Sequencing of Proteins from Silver-Stained Polyacrylamide Gels Mass Spectrometric Sequencing of Proteins from Silver-Stained Polyacrylamide Gels,” vol. 68, no. 5, pp. 850–858, 1996.

G. Bindea, B. Mlecnik, H. Hackl, P. Charoentong, M. Tosolini, A. Kirilovsky, W. H. Fridman, F. Pagès, Z. Trajanoski, and J. Galon, “ClueGO: A Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks,” Bioinformatics, vol. 25, no. 8, pp. 1091–1093, 2009.

P. Shannon, A. Markiel, 2 Owen Ozier, N. S. Baliga, J. T. Wang, D. Ramage, N. Amin, B. Schwikowski, and T. Ideker, “Cytoscape: a software environment for integrated models of biomolecular interaction networks,” Genome Res., no. 13, pp. 2498–2504, 2003.

M. Frantzi, A. Bhat, and A. Latosinska, “Clinical proteomic biomarkers: relevant issues on study design & technical considerations in biomarker development,” Clin. Transl. Med., vol. 3, no. 1, p. 7, 2014.

R. Huang, Z. Chen, L. He, N. He, Z. Xi, Z. Li, Y. Deng, and X. Zeng, “Mass spectrometry-assisted gel-based proteomics in cancer biomarker discovery: approaches and application,” Theranostics, vol. 7, no. 14, pp. 3559–3572, 2017.

S. Beloribi-Djefaflia, S. Vasseur, and F. Guillaumond, “Lipid metabolic reprogramming in cancer cells,” Oncogenesis, vol. 5, no. 1, p. e189, 2016.

M. W. Mosesson, “Fibrinogen and fibrin structure and functions,” J. Thromb. Haemost., vol. 3, no. 8, pp. 1894–1904, 2005.

Y. Luo, H. S. Kim, M. Kim, M. Lee, and Y. S. Song, “Elevated plasma fibrinogen levels and prognosis of epithelial ovarian cancer: A cohort study and meta-analysis,” J. Gynecol. Oncol., vol. 28, no. 3, pp. 1–12, 2017.

P. Chen, C. Wang, B. Cheng, E. U. Nesa, Y. Liu, Y. Jia, Y. Qu, Z. Jiang, J. Han, and Y. Cheng, “Plasma fibrinogen and serum albumin levels (FA score) act as a promising prognostic indicator in non-small cell lung cancer,” Onco. Targets. Ther., vol. 10, pp. 3107–3118, 2017.

F. Liu, H. Gao, C. Wu, and Z. Zhu, “The association of plasma fibrinogen with clinicopathological features and prognosis in esophageal cancer patients,” Oncotarget, vol. 8, no. 54, pp. 93029–93038, 2017.

Y. L. Tao, Y. Li, J. Gao, Z. G. Liu, Z. W. Tu, G. Li, B. Q. Xu, D. L. Niu, C. Bin Jiang, W. Yi, Z. Q. Li, J. Li, Y. M. Wang, Z. Bin Cheng, Q. D. Liu, L. Bai, C. Zhang, J. Y. Zhang, M. S. Zeng, and Y. F. Xia, “Identifying FGA peptides as nasopharyngeal carcinoma-associated biomarkers by magnetic beads,” J. Cell. Biochem., vol. 113, no. 7, pp. 2268–2278, 2012.

M. D. Berger, A. D. Heini, K. Seipel, B. Mueller, A. Angelillo-Scherrer, and T. Pabst, “Increased fibrinogen levels at diagnosis are associated with adverse outcome in patients with acute myeloid leukemia,” Hematol. Oncol., 2016.

Q. Wei, T. Niu, M. Wang, J. Yang, P. Liu, and Y. Yi, “A Revised Fibrinogen Cutoff Value in the Chinese Disseminated Intravascular Coagulation Scoring System May Provide a Better Prognostic Value for Hematological Malignancies,” Acta Haematol., vol. 137, no. 3, pp. 132–140, 2017.

M. Zamanian-Daryoush and J. A. DiDonato, “Apolipoprotein A-I and cancer,” Front. Pharmacol., vol. 6, no. NOV, pp. 1–10, 2015.

S. Borgquist, T. Butt, P. Almgren, D. Shiffman, T. Stocks, M. Orho-Melander, J. Manjer, and O. Melander, “Apolipoproteins, lipids and risk of cancer,” Int. J. Cancer, vol. 138, no. 11, pp. 2648–2656, 2016.

I. K. Quaye, “Haptoglobin, inflammation and disease,” Trans. R. Soc. Trop. Med. Hyg., vol. 102, no. 8, pp. 735–742, 2008.

W. Liu, B. Liu, Q. Cai, J. Li, X. Chen, and Z. Zhu, “Proteomic identification of serum biomarkers for gastric cancer using multi-dimensional liquid chromatography and 2D differential gel electrophoresis,” Clin. Chim. Acta, vol. 413, no. 13–14, pp. 1098–1106, 2012.

L. Sun, S. Hu, L. Yu, C. Guo, L. Sun, Z. Yang, J. Qi, and Y. Ran, “Serum haptoglobin as a novel molecular biomarker predicting colorectal cancer hepatic metastasis,” Int. J. Cancer, vol. 138, no. 11, pp. 2724–2731, 2016.

J. Park, J. S. Yang, G. Jung, H. I. Woo, H. D. Park, J. W. Kim, W. Huh, J. W. Ko, H. Kim, J. Y. Cho, and S. Y. Lee, “Subunit-specific mass spectrometry method identifies haptoglobin subunit alpha as a diagnostic marker in non-small cell lung cancer,” J. Proteomics, vol. 94, pp. 302–310, 2013.

D. Van Gent, P. Sharp, K. Morgan, and N. Kalsheker, “Serpins: Structure, function and molecular evolution,” Int. J. Biochem. Cell Biol., vol. 35, no. 11, pp. 1536–1547, 2003.

S. Pan, T. A. Brentnall, and R. Chen, “Proteomics analysis of bodily fluids in pancreatic cancer,” Proteomics, vol. 15, no. 15, pp. 2705–2715, 2015.

E. López-Árias, A. Aguilar-Lemarroy, L. Felipe Jave-Suárez, G. Morgan-Villela, I. Mariscal-Ramírez, M. Martínez-Velázquez, Á. H. Álvarez, A. Gutiérrez-Ortega, and R. Hernández-Gutiérrez, “Alpha 1-antitrypsin: A novel tumor-associated antigen identified in patients with early-stage breast cancer,” Electrophoresis, vol. 33, no. 14, pp. 2130–2137, 2012.

A. L. Trachte, S. E. Suthers, M. R. Lerner, J. S. Hanas, E. R. Jupe, A. E. Sienko, A. M. Adesina, S. a Lightfoot, D. J. Brackett, and R. G. Postier, “Increased expression of alpha-1-antitrypsin, glutathione S-transferase pi and vascular endothelial growth factor in human pancreatic adenocarcinoma.,” Am. J. Surg., vol. 184, no. 6, pp. 642-7-8, 2002.

Z. J. El-akawi, A. M. Abu-awad, and N. A. Khouri, “Alpha-1 Antitrypsin Blood Levels as Indicator for the Efficacy of Cancer Treatment,” World J Oncol, vol. 4, no. 2, pp. 83–86, 2013.

M. A. Blajchman and A. H. Özge-Anwar, “The role of the complement system in hemostasis,” Prog. Hematol., vol. 14, no. 3, pp. 149–182, 1986.

S. Mamidi, S. Höne, and M. Kirschfink, “The complement system in cancer: Ambivalence between tumour destruction and promotion,” Immunobiology, vol. 222, no. 1, pp. 45–54, 2017.

Y. Huang, L. Z. Li, C. Z. Zhang, C. Yi, L. L. Liu, X. Zhou, G. B. Xie, M. Y. Cai, Y. Li, and J. P. Yun, “Decreased expression of zinc-alpha2-glycoprotein in hepatocellular carcinoma associates with poor prognosis,” J. Transl. Med., vol. 10, no. 1, pp. 1–10, 2012.

I. Katafigiotis, S. I. Tyritzis, K. G. Stravodimos, C. Alamanis, K. Pavlakis, A. Vlahou, M. Makridakis, A. Katafigioti, S. D. Garbis, and C. A. Constantinides, “Zinc α2-glycoprotein as a potential novel urine biomarker for the early diagnosis of prostate cancer,” BJU Int., vol. 110, no. 11 B, pp. 688–693, 2012.

M. Rydén, T. Agustsson, J. Andersson, J. Bolinder, E. Toft, and P. Arner, “Adipose zinc-α2-glycoprotein is a catabolic marker in cancer and noncancerous states,” J. Intern. Med., vol. 271, no. 4, pp. 414–420, 2012.

V. Dubois, L. Delort, F. Mishellany, T. Jarde, H. Billard, C. Lequeux, O. Damour, F. Penault-Llorca, M. P. Vasson, and F. Caldefie-Chezet, “Zinc-α2-glycoprotein: A new biomarker of breast cancer?,” Anticancer Res., vol. 30, no. 7, pp. 2919–2925, 2010.

N. F. Endres, K. Engel, R. Das, E. Kovacs, and J. Kuriyan, “Regulation of the catalytic activity of the EGF receptor,” Curr. Opin. Struct. Biol., vol. 21, no. 6, pp. 777–784, 2011.

M. Wobus, M. Bornhäuser, A. Jacobi, M. Kräter, O. Otto, C. Ortlepp, J. Guck, G. Ehninger, C. Thiede, and U. Oelschlägel, “Association of the EGF-TM7 receptor CD97 expression with FLT3-ITD in acute myeloid leukemia,” Oncotarget, vol. 6, no. 36, pp. 38804–38815, 2015.

L. Anelli, A. Zagaria, N. Coccaro, G. Tota, L. Impera, C. F. Minervini, D. Pastore, A. Minervini, P. Casieri, G. Specchia, and F. Albano, “A novel t(4;16)(q25;q23.1) associated with EGF and ELOVL6 deregulation in acute myeloid leukemia,” Gene, vol. 529, no. 1, pp. 144–147, 2013.

A. A. Rehman, H. Ahsan, and F. H. Khan, “Alpha-2-macroglobulin: A physiological guardian,” J. Cell. Physiol., vol. 228, no. 8, pp. 1665–1675, 2013.

K. J. Clemetson, Chapter 9 Blood glycoproteins, vol. 29, no. PART B. Elsevier Masson SAS, 1997.

I. Lindner, N. Y. A. Hemdan, M. Buchold, K. Huse, M. Bigl, I. Oerlecke, A. Ricken, F. Gaunitz, U. Sack, A. Naumann, M. Hollborn, D. Thal, R. Gebhardt, and G. Birkenmeier, “Α2-Macroglobulin Inhibits the Malignant Properties of Astrocytoma Cells By Impeding Β-Catenin Signaling,” Cancer Res., vol. 70, no. 1, pp. 277–287, 2010.

E. F. Burgess, A. J. L. Ham, D. L. Tabb, D. Billheimer, B. J. Roth, S. S. Chang, M. S. Cookson, T. J. Hinton, K. L. Cheek, S. Hill, and J. A. Pietenpol, “Prostate cancer serum biomarker discovery through proteomic analysis of alpha-2 macroglobulin protein complexes,” Proteomics - Clin. Appl., vol. 2, no. 9, pp. 1223–1233, 2008.

S. Suman, T. Basak, P. Gupta, S. Mishra, V. Kumar, S. Sengupta, and Y. Shukla, “Quantitative proteomics revealed novel proteins associated with molecular subtypes of breast cancer,” J. Proteomics, vol. 148, pp. 183–193, 2016.

Dimensions

PlumX

Visitas a la página del resumen del artículo

1331

Descargas

Los datos de descarga aún no están disponibles.

Cómo citar

[1]
“Estudio proteómico 2DE-DIGE en plasma sanguíneo de pacientes en etapa infantil con leucemia linfoblástica aguda”, Rev. Colomb. Quim., vol. 48, no. 1, pp. 5–15, Jan. 2019, doi: 10.15446/rev.colomb.quim.v48n1.75170.

Licencia

Derechos de autor 2019 Revista Colombiana de Química

Creative Commons License

Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.

Los autores/as conservarán sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia de reconocimiento de Creative Commons (CC. Atribución 4.0) que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación en esta revista.

Los autores/as podrán adoptar otros acuerdos de licencia no exclusiva de distribución de la versión de la obra publicada (p. ej.: depositarla en un archivo telemático institucional o publicarla en un volumen monográfico) siempre que se indique la publicación inicial en esta revista.

Se permite y recomienda a los autores/as difundir su obra a través de Internet (p. ej.: en archivos telemáticos institucionales o en su página web) antes y durante el proceso de envío, lo cual puede producir intercambios interesantes y aumentar las citas de la obra publicada. (Véase El efecto del acceso abierto).